

Pediatric CIRB Meeting Agenda

May 8, 2025

I. Amendment

ACNS1821, A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (Version Date 04/08/25)

II. Amendment

ANBL1531, A Phase 3 Study of ¹³¹I-Metaiodobenzylguanidine (¹³¹I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379) (Version Date 04/04/25)

III. Continuing Review

AOST2032, A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma (Version Date 09/26/23)

IV. Amendment

AOST2032, A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma (Version Date 03/17/25)

V. Amendment

AGCT1531, A Phase 3 Study of Active Surveillance for Low risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors (Version Date 04/23/25)

VI. Continuing Review

ACNS2321, A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas (Version Date 07/15/24)

VII. Continuing Review

ALTE2131, Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer (Version Date 04/03/25)

VIII. Continuing Review

APAL2020SC, Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias (Version Date 04/22/24)
